The Optimization Of The Procedure For The Synthesis Of Ezetimibe

Ezetimibe is a novel lipid-lowering drug, as the first example of selective inhibition of cholesterol absorption. It attracts clinical attention because of its special action. The drug was first developed by Merck and Schering-Plough together. It occupied certain share of the lipid-lowering drug market, with a great prospects for development in good economic and social values. In order to improve the stability of the process and yield, reduce the costs, we chose a relatively simple synthetic route to optimize on the basis of a large number of literatures. This route make more reliable for industrial.